CCM
KRYS icon

Cinctive Capital Management’s Krystal Biotech KRYS Stock Holding History

Cinctive Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.08M Buy
16,367
+13,493
+469% +$4.03M 0.22% 138
2026
Q1 		$742K Buy
+2,874
New +$765K 0.05% 272

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cinctive Capital Management's KRYS Position: Q2 2026 in Review

Cinctive Capital Management increased its Krystal Biotech (KRYS) stake by 469% in Q2 2026, buying an estimated $4.03M and bringing the position to 16,367 shares worth $6.08M. The position accounts for 0.22% of the portfolio, ranked #138.

Cinctive Capital Management first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Cinctive Capital Management held 16,367 shares of Krystal Biotech worth $6.08M as of Q2 2026.
  • Cinctive Capital Management bought 13,493 Krystal Biotech shares in Q2 2026, an estimated $4.03M.
  • Krystal Biotech made up 0.22% of Cinctive Capital Management's portfolio in Q2 2026, its #138 holding.
  • Cinctive Capital Management first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Cinctive Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.